Prognosis in relation to blood pressure variability: con side of the argument

Kei Asayama; Fang-Fei Wei; Azusa Hara; Tine W Hansen; Yan Li; Jan A Staessen

doi:10.1161/HYPERTENSIONAHA.115.04808

Prognosis in relation to blood pressure variability: con side of the argument

Hypertension. 2015 Jun;65(6):1170-9; discussion 1179. doi: 10.1161/HYPERTENSIONAHA.115.04808. Epub 2015 Apr 27.

Authors

Kei Asayama¹, Fang-Fei Wei¹, Azusa Hara¹, Tine W Hansen¹, Yan Li¹, Jan A Staessen²

Affiliations

¹ From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (F.-F.W., A.H., J.A.S.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); the Steno Diabetes Center, Gentofte and Research Center for Prevention and Health, Copenhagen, Denmark (T.W.H.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (Y.L.); and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.).
² From the Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (F.-F.W., A.H., J.A.S.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); the Steno Diabetes Center, Gentofte and Research Center for Prevention and Health, Copenhagen, Denmark (T.W.H.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (Y.L.); and VitaK Research and Development, Maastricht University, Maastricht, The Netherlands (J.A.S.). jan.staessen@med.kuleuven.be.

PMID: 25916728
DOI: 10.1161/HYPERTENSIONAHA.115.04808

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Age Factors
Aged
Aged, 80 and over
Antihypertensive Agents / administration & dosage
Blood Pressure / drug effects
Blood Pressure / physiology*
Blood Pressure Determination / methods
Blood Pressure Monitoring, Ambulatory / methods
Circadian Rhythm / drug effects
Circadian Rhythm / physiology*
Evidence-Based Medicine
Female
Humans
Hypertension / drug therapy
Hypertension / physiopathology*
Male
Middle Aged
Observer Variation
Prognosis
Risk Assessment
Sex Factors

Substances

Antihypertensive Agents